Orris

Uti

The message just says "Uti" - could you clarify what you're asking about? Did you mean UTI (Urinary Tract Infection)? If so, let me know what you'd like to know - for example:
  • Symptoms and diagnosis
  • Treatment/antibiotics
  • Causes and risk factors
  • UTI in a specific population (pregnancy, children, elderly, recurrent UTIs)
Or if "Uti" refers to something else entirely, please give me a bit more context.

Treatment

Treatment for UTI differs quite a bit depending on the patient - could you tell me which situation you mean?
Asking for Preferences
The message just says "Uti" - could you clarify what you're asking about? Did you mean UTI (Urinary Tract Infection)? If so, let me know what you'd like to know - for example:
  • Symptoms and diagnosis
  • Treatment/antibiotics
  • Causes and risk factors
  • UTI in a specific population (pregnancy, children, elderly, recurrent UTIs)
Or if "Uti" refers to something else entirely, please give me a bit more context.Treatment for UTI differs quite a bit depending on the patient - could you tell me which situation you mean?
Asking for Preferences
The message just says "Uti" - could you clarify what you're asking about? Did you mean UTI (Urinary Tract Infection)? If so, let me know what you'd like to know - for example:
  • Symptoms and diagnosis
  • Treatment/antibiotics
  • Causes and risk factors
  • UTI in a specific population (pregnancy, children, elderly, recurrent UTIs)
Or if "Uti" refers to something else entirely, please give me a bit more context.Treatment for UTI differs quite a bit depending on the patient - could you tell me which situation you mean?
Reading File
Finding Sources
Searching PubMed

"urinary tract infections" AND treatment

Finding Sources
Reading File
Reading File
Finding Sources
I have enough to give a solid, well-organized answer. Here's UTI treatment across the main clinical scenarios:

UTI Treatment

1. Uncomplicated cystitis (adult women, no fever/flank pain)

First-line agents (per IDSA guidelines, reflected across Harrison's, Goldman-Cecil, and Tintinalli's):
  • Nitrofurantoin monohydrate/macrocrystals 100 mg twice daily x 5 days
  • TMP-SMX (trimethoprim-sulfamethoxazole DS, 160/800 mg) twice daily x 3 days - avoid if local resistance is ≥20% or if used in the last 3 months
  • Fosfomycin 3 g single oral dose - lower efficacy than the above but useful with resistant organisms (only ~2-3% resistance even in ESBL-producing E. coli)
  • Pivmecillinam 400 mg twice daily x 5 days (where available) - avoid if early pyelonephritis is suspected, as it's less effective at treating upper tract disease
Fluoroquinolones (ciprofloxacin, levofloxacin) are not first-line for uncomplicated cystitis - reserved for other indications due to resistance concerns and toxicity. Aminopenicillins (amoxicillin, amoxicillin-clavulanate) are also not recommended as first-line due to lower efficacy and Klebsiella selection (Tintinalli's Emergency Medicine, p. 91-5 table).

2. Acute pyelonephritis / complicated UTI

  • Outpatient (stable patients): oral fluoroquinolone or, if susceptible, TMP-SMX after an initial dose of a long-acting parenteral agent (e.g., ceftriaxone) is often given if a fluoroquinolone-resistant organism is a concern.
  • Inpatient (parenteral options): ciprofloxacin 400 mg IV q12h, ceftriaxone 1-2 g IV daily, cefotaxime, gentamicin/tobramycin ± ampicillin, piperacillin-tazobactam, cefepime, or a carbapenem (ertapenem, imipenem, meropenem) - choice guided by local resistance and severity.
  • Duration: 7-14 days total for most patients; men without immunocompromise may do well with just 7 days; up to 21 days if sepsis is present.
  • Switch parenteral to oral once clinically improved (Tintinalli's Emergency Medicine, Table 91-5/91-6).

3. Pregnancy

  • Asymptomatic bacteriuria must be treated in pregnancy (unlike in non-pregnant women) - untreated, up to 30% progress to pyelonephritis. Nitrofurantoin and other agents safe in pregnancy are used, with attention to trimester-specific safety (nitrofurantoin and TMP-SMX are generally avoided near term/first trimester per drug-specific guidance) (Brenner and Rector's The Kidney; Campbell-Walsh Urology).

4. Men

Data are more limited; treatment principles are similar to complicated UTI given higher likelihood of structural/prostatic involvement. Fluoroquinolones are often favored because they achieve good prostatic tissue penetration if prostatitis is a concern.

5. Recurrent UTI (>2 in 6 months or >3 in 12 months)

Treat the acute episode per the uncomplicated cystitis regimens (or complicated regimens if it's a true relapse rather than reinfection), then consider prophylaxis: continuous low-dose antibiotics, postcoital prophylaxis, or patient-initiated intermittent self-treatment. Address modifiable risk factors like spermicide use.

6. Catheter-associated UTI (CAUTI)

Remove or replace the catheter before collecting cultures and starting antibiotics; otherwise treated similarly to complicated UTI.
Recent systematic reviews/meta-analyses worth noting if you want more current comparative-efficacy data on complicated UTI/pyelonephritis treatments:
  • Wagenlehner et al. 2025, network meta-analysis of treatments for complicated UTI/pyelonephritis (PMID: 39817442)
  • Sivanandy et al. 2024, review of newer antibiotics (2016-2023) for complicated UTI (PMID: 39530664)
These don't contradict the textbook guidance above but reflect newer agents (e.g., newer beta-lactam/beta-lactamase inhibitor combinations) for resistant organisms - let me know if you'd like details on those newer drugs specifically.
This is a shared conversation. Sign in to Orris to start your own chat.